본문 바로가기
KERD
논문KCI 등재

The role of the farnesoid X receptor in kidney health and disease: a potential therapeutic target in kidney diseases

김창성|김수완|Bae Eun Hui|마성권|Kim Dong-Hyun|Park Jung Sun|Choi Hoon-In
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2023.12|Experimental and Molecular Medicine|제55권 |pp. 304-312|DOI 10.1038/s12276-023-00932-2

2

조회

0

다운로드

0

인용

0

참고문헌

주제분류생화학

초록

The prevalence of kidney diseases has been increasing worldwide due to the aging population and has results in an increased socioeconomic burden as well as increased morbidity and mortality. A deep understanding of the mechanisms underlying the physiological regulation of the kidney and the pathogenesis of related diseases can help identify potential therapeutic targets. The farnesoid X receptor (FXR, NR1H4) is a primary nuclear bile acid receptor that transcriptionally regulates bile acid homeostasis as well as glucose and lipid metabolism in multiple tissues. The roles of FXR in tissues other than hepatic and intestinal tissues are poorly understood. In studies over the past decade, FXR has been demonstrated to have a protective effect against kidney diseases through its anti-inflammatory and antifibrotic effects; it also plays roles in glucose and lipid metabolism in the kidney. In this review, we discuss the physiological role of FXR in the kidney and its pathophysiological roles in various kidney diseases, including acute kidney injury and chronic kidney diseases, diabetic nephropathy, and kidney fibrosis. Therefore, the regulatory mechanisms involving nuclear receptors, such as FXR, in the physiology and pathophysiology of the kidney and the development of agonists and antagonists for modulating FXR expression and activation should be elucidated to identify therapeutic targets for the treatment of kidney diseases.

Abstract

The prevalence of kidney diseases has been increasing worldwide due to the aging population and has results in an increased socioeconomic burden as well as increased morbidity and mortality. A deep understanding of the mechanisms underlying the physiological regulation of the kidney and the pathogenesis of related diseases can help identify potential therapeutic targets. The farnesoid X receptor (FXR, NR1H4) is a primary nuclear bile acid receptor that transcriptionally regulates bile acid homeostasis as well as glucose and lipid metabolism in multiple tissues. The roles of FXR in tissues other than hepatic and intestinal tissues are poorly understood. In studies over the past decade, FXR has been demonstrated to have a protective effect against kidney diseases through its anti-inflammatory and antifibrotic effects; it also plays roles in glucose and lipid metabolism in the kidney. In this review, we discuss the physiological role of FXR in the kidney and its pathophysiological roles in various kidney diseases, including acute kidney injury and chronic kidney diseases, diabetic nephropathy, and kidney fibrosis. Therefore, the regulatory mechanisms involving nuclear receptors, such as FXR, in the physiology and pathophysiology of the kidney and the development of agonists and antagonists for modulating FXR expression and activation should be elucidated to identify therapeutic targets for the treatment of kidney diseases.

참고문헌 (92)

  1. Hoste, E. A. J., "Global epidemiology and outcomes of acute kidney injury", Nat. Rev. Nephrol, 14, pp.607~625 (2018)
  2. Modica, S., "Deciphering the nuclear bile acid receptor FXR paradigm", Nucl. Recept. Signal, 8, pp.e005~ (2010)
  3. Calkin, A. C., "Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR", Nat. Rev. Mol. Cell. Biol, 13, pp.213~224 (2012)
  4. Makishima, M., "Identification of a nuclear receptor for bile acids", Science, 284, pp.1362~1365 (1999)
  5. Wang, H., "Endogenous bile acids are ligands for the nuclear receptor FXR", BAR, 1999, pp.3, 543~553
  6. Huber, R. M., "Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters", Gene, 290, pp.35~43 (2002)
  7. Zhang, Y., "Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation", J. Biol. Chem, 278, pp.104~110 (2003)
  8. Zhang, X., "Farnesoid X receptor(FXR)gene deficiency impairs urine concentration in mice", Proc. Natl Acad. Sci. USA, 111, pp.2277~2282 (2014)
  9. Chen, L., "A comprehensive map of mRNAs and their isoforms across All 14 renal tubule segments of mouse", J. Am. Soc. Nephrol, 32, pp.897~912 (2021)
  10. Xu, S., "Nuclear farnesoid X receptor attenuates acute kidney injury through fatty acid oxidation", Kidney Int, 101, pp.987~1002 (2022)
  11. Parks, D. J., "Bile acids : natural ligands for an orphan nuclear receptor", Science, 284, pp.1365~1368 (1999)
  12. Downes, M., "A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR", Mol. Cell, 11, pp.1079~1092 (2003)
  13. Thomas, A. M., "Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine", Hepatology, 51, pp.1410~1419 (2010)
  14. Lee, J., "Genomic analysis of hepatic farnesoid X receptor binding sites reveals altered binding in obesity and direct gene repression by farnesoid X receptor in mice", Hepatology, 56, pp.108~117 (2012)
  15. Zhan, L., "Genome-wide binding and transcriptome analysis of human farnesoid X receptor in primary human hepatocytes", PLoS ONE, 9, pp.e105930~ (2014)
  16. Li, S., "Bile acid G protein-coupled membrane receptor TGR5 modulates aquaporin 2-mediated water homeostasis", J. Am. Soc. Nephrol, 29, pp.2658~2670 (2018)
  17. Guo, C., "TGR5, not only a metabolic regulator", Front. Physiol, 7, pp.646~ (2016)
  18. Ferraris, J. D., "Tonicity-dependent regulation of osmoprotective genes in mammalian cells", Contrib. Nephrol, 152, pp.125~141 (2006)
  19. Xu, S., "Farnesoid X receptor is essential for the survival of renal medullary collecting duct cells under hypertonic stress", Proc. Natl Acad. Sci. USA, 115, pp.5600~5605 (2018)
  20. Alam, G., "Activation of farnesoid X receptor(FXR)induces crystallin zeta expression in mouse medullary collecting duct cells", Pflug. Arch, 472, pp.1631~1641 (2020)
  21. Pitzer, A. L., "ENaC in salt-sensitive hypertension : kidney and beyond", Curr. Hypertens. Rep, 22, pp.69~ (2020)
  22. Ilyaskin, A. V., "Activation of the human epithelial sodium channel(ENaC)by bile acids involves the degenerin site", J. Biol. Chem, 291, pp.19835~19847 (2016)
  23. Wang, X. P., "Murine epithelial sodium(Na(+))channel regulation by biliary factors", J. Biol. Chem, 294, pp.10182~10193 (2019)
  24. Hermann, M., "Nitric oxide in hypertension", J. Clin. Hypertens, 8, pp.17~29 (2006)
  25. Li, J., "FXR-mediated regulation of eNOS expression in vascular endothelial cells", Cardiovasc. Res, 77, pp.169~177 (2008)
  26. Li, C., "Farnesoid X receptor agonist CDCA reduces blood pressure and regulates vascular tone in spontaneously hypertensive rats", J. Am. Soc. Hypertens, 9, pp.507~516 (2015)
  27. Zhu, Y., "Renal Farnesoid X Receptor improves high fructose-induced saltsensitive hypertension in mice by inhibiting DNM3 to promote nitro oxide production", J. Hypertens, 40, pp.1577~1588 (2022)
  28. Bobulescu, I. A., "Renal lipid metabolism and lipotoxicity", Curr. Opin. Nephrol. Hypertens, 19, pp.393~402 (2010)
  29. Proctor, G., "Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes", Diabetes, 55, pp.2502~2509 (2006)
  30. Sun, L., "Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus", J. Biol. Chem, 277, pp.18919~18927 (2002)
  31. Jiang, T., "Diet-induced obesity in C57BL", 6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway, 2005, pp.280, 32317~32325
  32. Jiang, T., "Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy", Diabetes, 56, pp.2485~2493 (2007)
  33. Wang, X. X., "The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria", Am. J. Physiol. Ren. Physiol, 297, pp.F1587~F1596 (2009)
  34. Mencarelli, A., "Antiatherosclerotic effect of farnesoid X receptor", Am. J. Physiol. Heart Circ. Physiol, 296, pp.H272~H281 (2009)
  35. Miyazaki-Anzai, S., "Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5protects mice against atherosclerosis", PLoS ONE, 9, pp.e108270~ (2014)
  36. Miyazaki-Anzai, S., "Simultaneous inhibition of FXR and TGR5 exacerbates atherosclerotic formation", J. Lipid Res, 59, pp.1709~1713 (2018)
  37. Miyazaki-Anzai, S., "Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-", -mice with chronic kidney disease, 2010, pp.106, 1807~1817
  38. Jovanovich, A., "Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD", Am. J. Kidney Dis, 71, pp.27~34 (2018)
  39. Miyazaki-Anzai, S., "Free deoxycholic acid exacerbates vascular calcification in CKD through ER stress-mediated ATF4 activation", Kidney, 360(2), pp.857~868 (2021)
  40. Li, C., "Farnesoid X receptor activation inhibits TGFBR1", TAK1-mediated vascular inflammation and calcification via miR-135a-5p, 2020, pp.3, 327~
  41. Kellum, J. A., "Acute kidney injury", Nat. Rev. Dis. Prim, 7, pp.52~ (2021)
  42. Malek, M., "Renal ischemia", reperfusion injury; from pathophysiology to treatment, 2015, pp.4, 20~27
  43. Gai, Z., "Farnesoid X receptor activation protects the kidney from ischemiareperfusion damage", Sci. Rep, 7, pp.9815~ (2017)
  44. Luan, Z. L., "A naturally occurring FXR agonist, alisol B 23-acetate, protects against renal ischemia-reperfusion injury", Am. J. Physiol. Ren. Physiol, 321, pp.F617~F628 (2021)
  45. Zhu, J. B., "Farnesoid X receptor agonist obeticholic acid inhibits renal inflammation and oxidative stress during lipopolysaccharide-induced acute kidney injury", Eur. J. Pharmacol, 838, pp.60~68 (2018)
  46. Kim, D. H., "A dysregulated acetyl", SUMO switch of FXR promotes hepatic inflammation in obesity, 2015, pp.34, 184~199
  47. Kaushal, G. P., "Autophagy function and regulation in kidney disease", Biomolecules, 10, pp.100~ (2020)
  48. Lee, J. M., "Nutrient-sensing nuclear receptors coordinate autophagy", Nature, 516, pp.112~115 (2014)
  49. Seok, S., "Transcriptional regulation of autophagy by an FXR-CREB axis", Nature, 516, pp.108~111 (2014)
  50. Kim, D. H., "The critical role of FXR is associated with the regulation of autophagy and apoptosis in the progression of AKI to CKD", Cell Death Dis, 12, pp.320~ (2021)
  51. Ozkok, A., "Pathophysiology of cisplatin-induced acute kidney injury", Biomed. Res. Int, 2014, pp.967826~ (2014)
  52. Bae, E. H., "Farnesoid X receptor ligand prevents cisplatin-induced kidney injury by enhancing small heterodimer partner", PLoS ONE, 9, pp.e86553~ (2014)
  53. Zhang, L., "Knockout of farnesoid X receptor gene aggravates cisplatin-induced kidney injury", Zhong Nan Da Xue Xue Bao Yi Xue Ban, 47, pp.174~182 (2022)
  54. Jiang, X., "Ferroptosis : mechanisms, biology and role in disease", Nat. Rev. Mol. Cell. Biol, 22, pp.266~282 (2021)
  55. Kim, D. H., "Farnesoid X receptor protects against cisplatin-induced acute kidney injury by regulating the transcription of ferroptosis-related genes", Redox Biol, 54, pp.102382~ (2022)
  56. Zhang, Y., "Protective effects of dioscin against doxorubicin-induced nephrotoxicity via adjusting FXR-mediated oxidative stress and inflammation", Toxicology, 378, pp.53~64 (2017)
  57. Liu, Y., "Cellular and molecular mechanisms of renal fibrosis", Nat. Rev. Nephrol, 7, pp.684~696 (2011)
  58. Meng, X. M, "TGF-beta: the master regulator of fibrosis", Nat. Rev. Nephrol, 12, pp.325~338 (2016)
  59. Gu, Y. Y., "Diverse role of TGF-beta in kidney disease", Front. Cell Dev. Biol, 8, pp.123~ (2020)
  60. Zhao, K., "Activation of FXR protects against renal fibrosis via suppressing Smad3 expression", Sci. Rep, 6, pp.37234~ (2016)
  61. Liu, F., "Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis", Am. J. Physiol. Lung Cell. Mol. Physiol, 308, pp.L344~L357 (2015)
  62. Kim, D. H., "Src-mediated crosstalk between FXR and YAP protects against renal fibrosis", FASEB J, 33, pp.11109~11122 (2019)
  63. Li, S., "The farnesoid X receptor agonist EDP-305 reduces interstitial renal fibrosis in a mouse model of unilateral ureteral obstruction", FASEB J, 33, pp.7103~7112 (2019)
  64. Ma, K., "Farnesoid X receptor is essential for normal glucose homeostasis", J. Clin. Invest, 116, pp.1102~1109 (2006)
  65. Zhou, W., "Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism", Mol. Cell. Endocrinol, 549, pp.111616~ (2022)
  66. Tuttle, K. R., "Molecular mechanisms and therapeutic targets for diabetic kidney disease", Kidney Int, 102, pp.248~260 (2022)
  67. Pineda Torra, I., "Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor", Mol. Endocrinol, 17, pp.259~272 (2003)
  68. Watanabe, M., "Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c", J. Clin. Invest, 113, pp.1408~1418 (2004)
  69. Matsukuma, K. E., "Coordinated control of bile acids and lipogenesis through FXR-dependent regulation of fatty acid synthase", J. Lipid Res, 47, pp.2754~2761 (2006)
  70. Caron, S., "Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes", Mol. Cell. Biol, 33, pp.2202~2211 (2013)
  71. Zhou, B., "Activation of farnesoid X receptor downregulates visfatin and attenuates diabetic nephropathy", Mol. Cell. Endocrinol, 419, pp.72~82 (2016)
  72. Wang, X. X., "Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model", Diabetes, 59, pp.2916~2927 (2010)
  73. Wang, X. X., "FXR", TGR5 dual agonist prevents progression of nephropathy in diabetes and obesity, 2018, pp.29, 118~137
  74. Lu, J., "Association of serum bile acids profile and pathway dysregulation with the risk of developing diabetes among normoglycemic chinese adults : findings from the 4C study", Diabetes Care, 44, pp.499~510 (2021)
  75. Wei, H., "QiDiTangShen granules modulated the gut microbiome composition and improved bile acid pro fi les in a mouse model of diabetic nephropathy", Biomed. Pharmacother, 133, pp.111061~ (2021)
  76. Marquardt, A., "Farnesoid X receptor agonism protects against diabetic tubulopathy : potential add-on therapy for diabetic nephropathy", J. Am. Soc. Nephrol, 28, pp.3182~3189 (2017)
  77. Li, F., "Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity", Nat. Commun, 4, pp.2384~ (2013)
  78. Liu, Y., "Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra-and extrahepatic cholestasis", J. Clin. Invest, 112, pp.1678~1687 (2003)
  79. Sun, L., "Gut microbiota and intestinal FXR mediate the clinical benefits of metformin", Nat. Med, 24, pp.1919~1929 (2018)
  80. Li, L., "FXR activation alleviates tacrolimus-induced post-transplant diabetes mellitus by regulating renal gluconeogenesis and glucose uptake", J. Transl. Med, 17, pp.418~ (2019)
  81. Kemper, J. K., "Regulation of FXR transcriptional activity in health and disease:Emerging roles of FXR cofactors and post-translational modifications", Biochim. Biophys. Acta, 1812, pp.842~850 (2011)
  82. Pellicciari, R., "6alpha-ethyl-chenodeoxycholic acid(6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity", J. Med. Chem, 45, pp.3569~3572 (2002)
  83. Erstad, D. J., "Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP-305, a novel farnesoid X receptor agonist", Hepatol. Commun, 2, pp.821~835 (2018)
  84. Akwabi-Ameyaw, A., "Conformationally constrained farnesoid X receptor(FXR)agonists : Naphthoic acid-based analogs of GW 4064", Bioorg. Med. Chem. Lett, 18, pp.4339~4343 (2008)
  85. Tully, D. C., "Discovery of tropifexor(LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis(NASH)", J. Med. Chem, 60, pp.9960~9973 (2017)
  86. Trauner, M., "The nonsteroidal farnesoid x receptor agonist cilofexor(GS-9674)improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis", Hepatology, 70, pp.788~801 (2019)
  87. Flatt, B., "Discovery of XL335(WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor(FXR)", J. Med. Chem, 52, pp.904~907 (2009)
  88. Chianelli, D., "Nidufexor(LMB763), a novel FXR modulator for the treatment of nonalcoholic steatohepatitis", J. Med. Chem, 63, pp.3868~3880 (2020)
  89. Wagner, B., "MET409, a potent, non-bile acid sustained FXR Agonist, shows rapid disease reversal in a diet-induced obese mouse model of biopsy-confirmed nash", Hepatology, 68, pp.1006~1006 (2018)
  90. methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic acid : a novel FXR agonist for the treatment of dyslipidemia, "J. Med. Chem", 2015, 9768~9772
  91. Radreau, P., "Vitro and in vivo characterization of Eyp001 a novel, potent and selective Fxr agonist now in a phase 2 clinical trial in nash", Hepatology, 70, pp.1267~1267 (2019)
  92. Cui, J., "Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump", J. Biol. Chem, 278, pp.10214~10220 (2003)

관련 논문AI추천

Bile Acid Receptor Farnesoid X Receptor: A Novel Therapeutic Target for Metabolic Diseases황성순한국지질동맥경화학회 · 지질·동맥경화학회지2017 · 제6권 제1호Transcriptional coordination of hepatic autophagy by nutrient-sensing nuclear receptor PPARα and FXR이재만대한소아내분비학회 · Annals of Pediatric Endocrinology & Metabolism2016 · 제21권 제4호담즙산과 대사질환노지혜, 윤정현한국임상약학회 · 한국임상약학회지2018 · 제28권 제4호Bioactive metabolites: A clue to the link between MASLD and CKD?Christopher D. Byrne, Dan-Qin Sun, Giovanni Targher, Jia-Hui Zhang, Liang Luo, Li-Li Chen, Ming-Hua Zheng, Wen-Ying Chen, Yan Ni대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Ursodeoxycholic acid decreases age-related adiposity and inflammation in mice박상철, 배진식, 신은지, 오병철, 오아름, 이정훈, 차지영생화학분자생물학회 · BMB Reports2016 · 제49권 제2호The role of inflammation in diabetic kidney diseaseJu-Young Moon, Su Woong Jung대한내과학회 · The Korean Journal of Internal Medicine2021 · 제36권 제4호

이 간행물의 다른 논문 (225건)

Endothelial senescence in vascular diseases: current understanding and future opportunities in senotherapeutics김성영, Han Yeaeunpp. 1-12Grave-to-cradle: human embryonic lineage tracing from the postmortem bodyKu Eu Jeong, Choi Seock Hwan, Choi Yujin Angelina, Oh Ji Wonpp. 13-21Chromatin and noncoding RNA-mediated mechanisms of gastric tumorigenesisKim Tae-Hee, Loe Adrian Kwan Ho, Zhu Lexinpp. 22-31TPX2 prompts mitotic survival via the induction of BCL2L1 through YAP1 protein stabilization in human embryonic stem cellsCha Hyuk-Jin, Kim Yun-Jeong, Go Young-Hyun, 정호창, Kwon Eun-Ji, Kim Seong-Min, Cheong Hyun Sub, Kim Wantae, Shin Hyoung Doo, Lee Haeseungpp. 32-42ZBTB7A suppresses glioblastoma tumorigenesis through the transcriptional repression of EPB41L5Nam Hae Yun, 김성학, 김승후, 최경철, Park Seung-Ho, Song Ji-Hye, Jeong Ji-Hoon, Kim Hyunhee, Jeong Minseok, Kong Min-Jeong, Son Jihyun, Jeong Ji-Eunpp. 43-54
원문 보기